Marc Hickel thought his battle with prostate cancer was over after surgery and radiation treatment. But five years later, scarring from the radiation created new, debilitating problems that left him ...

BEL AIR, Md. — Marc Hickel thought his battle with prostate cancer was over after surgery and radiation treatment. But five years later, scarring from the radiation created new, debilitating problems ...

Rectal diazepam pretreatment led to a 78% relative risk reduction in drug retention failure and a 68% reduction in bladder spasms, improving treatment consistency and reducing drug waste. The study ...

A treatment’s safety and efficacy remain the gold standard in therapeutic innovation, but the most transformative medicines also succeed on another critical front: how seamlessly they integrate into a ...

A patient advocate with overactive bladder talks about how the condition affected her ability to work and the importance of getting treatment. Darlene C. worked as a nurse for nearly three decades.

An expert discusses how clinics can successfully implement gene therapy workflows by establishing strong institutional protocols, assigning dedicated clinic coordinators, and using strategies like ...

If you're like most people, you probably don't give much thought to your bladder or bowel function unless something goes wrong. Unfortunately, though, these types of dysfunctions are common among ...

Nadofaragene firadenovec-vncg is an FDA-approved therapy for bacille Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). Bladder spasms and medication leakage during ...

Last week, “The Valley” star Zack Wickham opened up about his experience with “scrotox” — yes, that’s Botox in the scrotum. But while that down-below neurotoxin treatment is for cosmetic reasons, a ...

What Is BCG Treatment for Bladder Cancer? Bacillus Calmette-Guérin (BCG) is the main immunotherapy used to treat early-stage bladder cancer. Immunotherapy uses your immune system to fight cancer. BCG ...

CG Oncology, Inc. announced encouraging results from its Phase 3 BOND-003 Cohort C study of cretostimogene grenadenorepvec, an investigational monotherapy for high-risk non-muscle invasive bladder ...